Continuing antidepressant medications during pregnancy is associated with a reduced risk of postpartum depression compared to stopping or intermittent use.
Severity of depressive symptoms at pregnancy onset strongly predicts postpartum depression risk, emphasizing the importance of early screening.
Risk reduction benefits of antidepressant continuation do not significantly differ across racial, ethnic, or age groups, supporting broad clinical applicability.
Shared decision-making informed by prenatal depressive symptom severity is crucial to optimize maternal mental health outcomes.
